IGC Pharma Inc.

04/26/2024 | Press release | Distributed by Public on 04/26/2024 09:15

IGC PHARMA Announces Positive Interim Results for IGC-AD1 in Reducing Alzheimer’s Agitation

IGC Pharma Advances in Alzheimer's Research from Pre-clinical Studies to Phase Two Trials with its Novel Therapy Candidate IGC-AD1

By: Faith Ashmore Benzinga Staff Writer Alzheimer's disease, a progressive neurological disorder, affects around 24 million individuals worldwide. It is characterized by memory loss, cognitive decline and behavioral changes. The impact

Read More »